Clinical trials: JIA
Rheumatic Diseases, Pediatric ALL
Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire
No tool has been found to evaluate behaviors that may hinder or facilitate physical activity in individuals with pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric ALL, Children, Only
- Trial name
- NCT06460766
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul University - Cerrahpasa
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
The purpose of this study is to compare two aggressive drug regimens for children with poly-juvenile idiopathic arthritis (JIA) and extended oligo JIA.
- Conditions
- Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
- Trial name
- NCT00443430
- Testing
- methotrexate, methotrexate - etanercept - prednisolone arm
- Where
- 15 sites in United States
- Volunteers
- 85 people
- Sponsor
- Seattle Children's Hospital
Juvenile Idiopathic Arthritis
OHRQoL Evaluation After Functional Therapy in JIA Patients
The aim of the study was to determine the changes in Oral Health-Related Quality of Life (OHRQoL) in patients with juvenile idiopathic arthritis (JIA) and temporomandibular joint (TMJ) disorders who underwent functional therapy…
- Trial name
- NCT03008681
- Testing
- Andresen functional removable orthodontic appliance
- Where
- Italy
- Volunteers
- 93 people
- Sponsor
- University of Messina
Juvenile Idiopahtic Arthritis
Improving Outcomes for Juvenile Idiopathic Arthritis
Children and parents often experience uncertainty and stress when juvenile idiopathic arthritis (JIA) is first diagnosed, which creates a need for structured support.
- Trial name
- NCT07659223
- Testing
- The intervention was a one year support program JASP-1
- Where
- Sweden
- Volunteers
- 116 people
- Sponsor
- Region Stockholm
Juvenile Idiopathic Arthritis
The iPeer2Peer Program for Adolescents With Juvenile Idiopathic Arthritis
The iPeer2Peer program matches teens with arthritis to an older mentor who has learned to manage their arthritis well and can support them emotionally and socially.
- Trial name
- iPeer2Peer (NCT03116763)
- Testing
- iPeer2Peer Mentorship, Active Comparator: Control Group
- Where
- 6 sites in Canada
- Volunteers
- 164 people
- Sponsor
- The Hospital for Sick Children
Rheumatoid Arthritis
Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children
This postmarketing surveillance study will evaluate the safety profile of Enbrel (etanercept) in an Indian population. It will provide surveillance on a currently approved indication for Enbrel of reducing symptoms and inhibiting…
- Trial name
- NCT00484809
- Testing
- Enbrel (Etanercept)
- Volunteers
- 100 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Juvenile Idiopathic Arthritis
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.
- Trial name
- NCT00144599
- Testing
- MRA(Tocilizumab)
- Volunteers
- 56 people
- Sponsor
- Chugai Pharmaceutical
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations.
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
- Trial name
- NCT04833465
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Children's National Research Institute
Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the…
- Conditions
- Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia, Autoimmune Diseases, Autoimmune Anemia
- Trial name
- ATRACTion (NCT04902807)
- Testing
- Collection of samples
- Where
- France
- Volunteers
- 325 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Spinal Cord Injuries, Spina Bifida
Downstream Effects of Personalized 'Top-down' Participation-based Interventions Among Youth With Physical Disabilities
Participation in community-based activities is essential to the health and well-being of youth with physical disabilities; yet, it is extremely restricted.
- Conditions
- Spinal Cord Injuries, Spina Bifida, Musculoskeletal Disorder, Juvenile Arthritis
- Trial name
- NCT05784285
- Testing
- Engagement in a 8-week community-based activity program
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- McGill University
Juvenile Idiopahtic Arthritis
JIA Toolbox Feasibility Study
Juvenile Idiopathic Arthritis (JIA) is a long-term rheumatic disease affecting approximately 15,000 children and young people (CYP) in the UK.
- Trial name
- NCT07543575
- Testing
- Heating prototype (Prototype 1), Physio tool (Prototype 2), Communication tool (Prototype 3)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Sheffield Children's NHS Foundation Trust
Systemic Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
- Trial name
- NCT00144612
- Testing
- MRA(Tocilizumab)
- Volunteers
- 60 people
- Sponsor
- Chugai Pharmaceutical
Systemic-Onset Juvenile Idiopathic Arthritis
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
1. Main objective: To test the efficacy of anakinra treatment in children or young adults with corticosteroid-resistant or -dependent Systemic-Onset Juvenile Idiopathic Arthritis (SO-JIA) 2.
- Trial name
- NCT00339157
- Testing
- Anakinra, Pneumo23
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Juvenile Idiopathic Arthritis, Diabetes type1
Host-microbiota-environment Interactions
Two types of inflammatory and autoimmune diseases (excluding monogenic diseases) can be distinguished in children: those similar to adult diseases but with an early onset (type 1 diabetes, inflammatory diseases of the…
- Conditions
- Juvenile Idiopathic Arthritis, Diabetes type1, Inflammatory Bowel Diseases
- Trial name
- MIP-1 (NCT05176795)
- Testing
- Stool sample
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Juvenile Idiopathic Arthritis
Cost of Care for Juvenile Idiopathic Arthritis
This project seeks to collect data on healthcare utilization and expenditure rates in Juvenile Idiopathic Arthritis (JIA) patients from across the US, correlate these costs with disease activity and outcome measures and determine…
- Trial name
- NCT01469897
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- The Cleveland Clinic
Juvenile Idiopathic Arthritis
Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA. 1.
- Trial name
- Enbrel-JIA (NCT01145352)
- Testing
- Etanercept (genetical recombination)
- Where
- Japan
- Volunteers
- 113 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis (JIA)
HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis
Methodology: Randomized, double-blind, AB/BA cross-over study with a washout period of 12 weeks. Treatment Duration: 8 weeks per group General Objectives: To assess the efficacy and safety of multiple intravenous infusions of…
- Trial name
- NCT06623240
- Testing
- allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals